Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

ract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease and is administered by intramuscular injection. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestation age), and children with hemodynamically significant CHD. Synagis has been used in more than one million children in the U.S. since its introduction in 1998. The first dose of Synagis should be administered prior to commencement of the RSV season. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.

Very rare cases (<1 per 100,000 patients) of anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. Cases of anaphylaxis were reported following re-exposure to Synagis and rare severe hypersensitivity reactions occurred on initial exposure or re-exposure. If a severe hypersensitivity reaction occurs, therapy with Synagis should be permanently discontinued. If milder hypersensitivity reaction occurs, caution should be used on re-administration of Synagis.

In clinical trials, the most common adverse events occurring at least 1 percent more frequently in Synagis-treated patients than controls were upper respiratory infection, otitis media, fever and rhinitis. Cyanosis and arrhythmia were seen in children with CHD.

For full prescribing information for Synagis, see the company's website at: www.medimmune.com/products/synagis/index.asp.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the ar
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/18/2014)... , Sept. 18, 2014 This BCC Research report ... of major players, market growth and size, and opportunities for ... and revenue through 2018. Patent analysis in the report focuses ... the U.S., Europe and ... - Define and discuss the global medical device technologies market. ...
(Date:9/18/2014)... , Sept. 18, 2014  Iliad Neurosciences, Inc., a ... diagnosing and treating Autism Spectrum Disorders (ASD) announced today ... with The Research Foundation for The State University of ... provide a new biomarker to identify an abnormality in ... ASD. This biomarker is expected to be available for ...
(Date:9/18/2014)... Pharma IQ, after huge demand ... Countdown calendar to cover the years 2014 - 2018 ... shows the serialisation requirements around the globe and the ... For companies dealing with international markets, serialisation ... they will have to comply with new regulations coming ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company ... therapeutic agents for the treatment of Alzheimer,s and ... filed a response and request for continued examination ... 10/084,380, one of several applications pending in the ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... chief financial officer, will present an overview of the ... The VIVUS presentation will take place at the ... at 9:30 a.m. MST.  A live webcast and 30-day ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3
(Date:9/18/2014)... LEXINGTON, Ky (Sept. 17, 2014) -- Two independent ... PhD, of the University of Kentucky, and Charles ... published important studies exploring the role that a ... cardiovascular disease. , According to Whiteheart, previous genome-wide ... as a factor that regulates a protein called ...
(Date:9/18/2014)... release is available in German . ... host strategy not to fight a pathogen tooth and nail, but ... term. One key feature of tolerance is that the disease only ... host carries a high pathogen load. , Roland Regoes, a senior ... this approach to HIV. He set about investigating whether there are ...
(Date:9/18/2014)... CAMBRIDGE, Massachusetts, U.S.A., September 18, 2014 -- BGI ... sequencing service to Denmark-based DLF-Trifolium and the Department ... University in an effort to develop a series ... genomic selection (GS) methods. , GS is a ... contrast to the traditional QTL-based selection, uses information ...
(Date:9/18/2014)... September 18, 2014 CRDF Global ... first ever digital edition – rich with videos, ... of how CRDF Global empowers scientists and innovators ... of government, corporate, foundation and individual supporters, CRDF ... innovators in research, training and entrepreneurship. , The ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Research conducted ... Allegheny Health Network has documented improved survival ... surgical removal of the tumors along with stereotactic radiosurgery. ... of ASTRO (American Society for Radiation Oncology) ... uses numerous precisely focused radiation beams to treat tumors ...
Breaking Medicine News(10 mins):Health News:University of Kentucky research explores STXBP5 gene and its role in blood clotting 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:BGI Tech, DLF-Trifolium A/S, and Aarhus University applying genomic selection methods 2Health News:CRDF Global Launches Media-Rich Digital Edition of Annual Report, Tells Story of Empowering Scientists and Innovators around the World in 2013 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3
... to detect suspicious activity in airports, stadiums and other ... researcher who invented them to find and measure potentially ... professor of Computer Science and one of the world,s ... computer imaging, has received $400,000 from the National Institutes ...
... about the importance of eye assessments for babies during June,s ... 2 When should a parent schedule a comprehensive eye ... at 6 months, the average baby has reached a number ... the first eye and vision assessment. , , According ...
... for space headache to be established as a new ... astronauts, published in the June issue of Cephalalgia ... headaches are normally caused by space motion sickness, after ... no connection. "Our research shows that space flights ...
... device will facilitate single port access laparoscopic surgery , ... privately held biomaterials-based medical device company, announced today that ... and Drug Administration to market the InnoPort(TM) to facilitate ... The InnoPort is inserted into the abdomen to perform ...
... , - Free health clinics facing crisis of increasing demand, ... hand in helping make donation possible , , - ... banks in December , , RICHMOND, Va., June 2 ... announced today it is donating $1 million to free health ...
... ... at trial, and bring Attorneys state of the art fall prevention and protection training. ... (PRWEB) June ... settlements, assist representation at trial, and bring Attorneys state of the art fall prevention ...
Cached Medicine News:Health News:UCF researcher developing computer program to detect, measure brain tumors 2Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 2Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 3Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 4Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 5Health News:Researchers call for new space headache category following astronauts' survey 2Health News:Innovia Receives FDA Clearance For The InnoPort(TM) 2Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 2Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 3Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 4Health News:Fall Prevention/Protection - Slip and Fall Accredited Training for Legal Practices 2
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
... EVS has an ergonomic stapler ... mechanism which requires a single ... locks onto the target vessel ... site before, during and after ...
Medicine Products: